Study on bioaerosol diffusion and deposition in a mobile BSL-4 laboratory based on air age analysis

Biosafety issues have aroused global concern, especially after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron strain of corona virus disease 2019 (COVID-19) caused incalculable human and property losses. Laboratory-acquired infections (LAIs) caused by improper operations or accidents are frequently reported. Research is urgently needed for a mobile biosafety level-4 (BSL-4) laboratory with a high risk for exposure. Deposition characteristics and the spatial distribution of bioaerosols under two typical cases were studied in this paper. Based on the age of air and simulation of airflow pattern, a detailed analysis of infection risk and the distribution of bioaerosols was conducted. The deposition characteristics of particles on different surfaces were analyzed based on particle tracking technology. The results showed that the removal rate of bioaerosols was lower in the space area of the laboratory from 1.6 m above the ground. The distribution of high-risk areas is affected by the coupling of equipment layout and pollution sources, mainly located downstream of the main airflow in the laboratory, and the particle concentration was eight times that of the low-risk areas. More than half of bioaerosol particles are deposited on laboratory equipment and walls. The number of particles deposited on the wall was the largest, accounting for 25.02% of the total. The unit area deposition ratio of the experimental table was the highest, which was 6.14 %/m2. The main deposition area of each surface was determined, which could be of guiding significance to the determination of the key disinfection location of the mobile BSL-4 laboratory. © 2023 Elsevier Ltd

Corrigendum: Evaluation of the SARS-CoV-2 Inactivation Efficacy Associated With Buffers From Three Kits Used on High-Throughput RNA Extraction Platforms.

[This corrects the article DOI: 10.3389/fcimb.2021.716436.].

Evaluation of the SARS-CoV-2 Inactivation Efficacy Associated With Buffers From Three Kits Used on High-Throughput RNA Extraction Platforms.

Rapid and demonstrable inactivation of SARS-CoV-2 is crucial to ensure operator safety during high-throughput testing of clinical samples. The inactivation efficacy of SARS-CoV-2 was evaluated using commercially available lysis buffers from three viral RNA extraction kits used on two high-throughput (96-well) RNA extraction platforms (Qiagen QIAcube HT and the Thermo Fisher KingFisher Flex) in combination with thermal treatment. Buffer volumes and sample ratios were chosen for their optimised suitability for RNA extraction rather than inactivation efficacy and tested against a representative sample type: SARS-CoV-2 spiked into viral transport medium (VTM). A lysis buffer mix from the MagMAX Pathogen RNA/DNA kit (Thermo Fisher), used on the KingFisher Flex, which included guanidinium isothiocyanate (GITC), a detergent, and isopropanol, demonstrated a minimum inactivation efficacy of 1 × 105 tissue culture infectious dose (TCID)50/ml. Alternative lysis buffer mixes from the MagMAX Viral/Pathogen Nucleic Acid kit (Thermo Fisher) also used on the KingFisher Flex and from the QIAamp 96 Virus QIAcube HT Kit (Qiagen) used on the QIAcube HT (both of which contained GITC and a detergent) reduced titres by 1 × 104 TCID50/ml but did not completely inactivate the virus. Heat treatment alone (15 min, 68°C) did not completely inactivate the virus, demonstrating a reduction of 1 × 103 TCID50/ml. When inactivation methods included both heat treatment and addition of lysis buffer, all methods were shown to completely inactivate SARS-CoV-2 inactivation against the viral titres tested. Results are discussed in the context of the operation of a high-throughput diagnostic laboratory.

Biosafety Concerns During the Collection, Transportation, and Processing of COVID-19 Samples for Diagnosis.

The coronavirus disease 2019 (COVID-19) pandemic, which started in China, has created a panic among the general public and health care/laboratory workers. Thus far, there is no medication or vaccine to prevent and control the spread of COVID-19. As the virus is airborne and transmitted through droplets, there has been significant demand for face masks and other personal protective equipment to prevent the spread of infection. Health care and laboratory workers who come in close contact with infected people or material are at a high risk of infection. Therefore, robust biosafety measures are required at hospitals and laboratories to prevent the spread of COVID-19. Various diagnostic platforms including of serological, molecular and other advanced tools and techniques have been designed and developed for rapid detection of SARS-CoV-2 and each has its own merits and demerits. Molecular assays such as real-time reverse transcriptase polymerase chain reaction (rRT-PCR) has been used worldwide for diagnosis of COVID-19. Samples such as nasal swabs or oropharyngeal swabs are used for rRT-PCR. Laboratory acquired infection has been a significant problem worldwide, which has gained importance during the current pandemic as the samples for rRT-PCR may contain intact virus with serious threat. COVID-19 can spread to workers during the sampling, transportation, processing, and disposal of tested samples. Here, we present an overview on advances in diagnosis of COVID-19 and details the issues associated with biosafety procedures and potential safety precautions to be followed during collection, transportation, and processing of COVID-19 samples for laboratory diagnosis so as to avoid virus infection.